Autoimmune Diseases

We are delighted to welcome Dr Benjamin Kaffenberger, Associate Professor of Dermatology at The Ohio State University Wexner Medical Center, to the touchDERMATOLOGY Expert Faculty. A leading expert in complex skin conditions such as pyoderma gangrenosum, DRESS syndrome, and SJS/TEN, Kaffenberger brings extensive clinical and research experience in drug reactions, wound care, and hospital dermatology.

Vilobelimab, a monoclonal anti-C5a antibody, is emerging as a promising treatment for pyoderma gangrenosum (PG), a rare and chronic autoimmune skin disorder characterized by painful ulcerations. With no approved therapies in the USA or Europe, there remains a significant unmet need for effective treatment.

We are delighted to announce that Professor Luis FC Ensina has joined the Expert Faculty of touchDERMATOLOGY. A distinguished allergologist, Professor Ensina is renowned for his expertise in urticaria, drug allergies and angioedema. His extensive contributions to clinical care, research and education have established him as a global leader in allergy and immunology. As a […]

Briquilimab, an anti-c-Kit monoclonal antibody, is being investigated for its ability to selectively deplete mast cells and alleviate the symptoms of CSU. At this year’s American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress (San Diego, CA, USA; 28 February–3 March 2025), the initial results from BEACON (ClinicalTrials.gov identifier: NCT06162728), a phase Ib/IIa dose-escalation study of briquilimab in adults with CSU, were presented.3,4

Current treatment options for flares of symptomatic oral lichen planus primarily include topical corticosteroids as the first-line therapy. Second- and third-line treatments range from topical calcineurin inhibitors to systemic corticosteroids, systemic retinoids and topical or systemic immunomodulators.5